Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer A, Vetter M, De Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, De Vries AC, Van Der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Levy C (2020)
Publication Type: Journal article
Publication year: 2020
Journal
Book Volume: 18
Pages Range: 179-+
Journal Issue: 1
DOI: 10.1016/j.cgh.2019.05.013
Abstract
BACKGROUND & AIMS: Gut-homing lymphocytes that express the integrin alpha 4 beta 7 and CCR9 might contribute to development of primary sclerosing cholangitis (PSC). Vedolizumab, which blocks the integrin alpha 4 beta 7, is used to treat patients with inflammatory bowel diseases (IBD), but there are few data on its efficacy in patients with PSC. We investigated the effects of vedolizumab in a large international cohort of patients with PSC and IBD.
Authors with CRIS profile
Andreas Kremer
Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology
Marcel Vetter
Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology
Involved external institutions
California Pacific Medical Center
United States (USA) (US)
University of Alberta
Canada (CA)
University of Amsterdam
Netherlands (NL)
University of Birmingham
United Kingdom (GB)
Azienda Ospedaliero Universitaria Ospedali Riuniti Ancona
Italy (IT)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
University of Oxford
United Kingdom (GB)
Karolinska Institute
Sweden (SE)
Massachusetts General Hospital
United States (USA) (US)
Yale University
United States (USA) (US)
University of Gothenburg / Göteborgs universitet
Sweden (SE)
Erasmus University Medical Center (MC)
Netherlands (NL)
University of Copenhagen
Denmark (DK)
University of Padua / Universita degli Studi di Padova
Italy (IT)
University of Miami
United States (USA) (US)
University of California Davis (UCDAVIS)
United States (USA) (US)
University of Washington
United States (USA) (US)
Medizinische Universität Wien
Austria (AT)
United States (USA) (US)
University of Alberta
Canada (CA)
University of Amsterdam
Netherlands (NL)
University of Birmingham
United Kingdom (GB)
Azienda Ospedaliero Universitaria Ospedali Riuniti Ancona
Italy (IT)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
University of Oxford
United Kingdom (GB)
Karolinska Institute
Sweden (SE)
Massachusetts General Hospital
United States (USA) (US)
Yale University
United States (USA) (US)
University of Gothenburg / Göteborgs universitet
Sweden (SE)
Erasmus University Medical Center (MC)
Netherlands (NL)
University of Copenhagen
Denmark (DK)
University of Padua / Universita degli Studi di Padova
Italy (IT)
University of Miami
United States (USA) (US)
University of California Davis (UCDAVIS)
United States (USA) (US)
University of Washington
United States (USA) (US)
Medizinische Universität Wien
Austria (AT)
How to cite
APA:
Lynch, K.D., Chapman, R.W., Keshav, S., Montano-Loza, A.J., Mason, A.L., Kremer, A.,... Levy, C. (2020). Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 18(1), 179-+. https://doi.org/10.1016/j.cgh.2019.05.013
MLA:
Lynch, Kate D., et al. "Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases." Clinical Gastroenterology and Hepatology 18.1 (2020): 179-+.
BibTeX: Download